🔗 Share this article

The first new treatments for gonorrhoea in many years are being described as a "huge turning point" in the battle against increasingly resistant strains of the infection, according to researchers.

A Worldwide Health Concern

The sexually transmitted infection are increasing globally, with estimates suggesting over 82 million infections per year. Especially elevated rates are seen in Africa and nations within the World Health Organization's designated area, which spans from China and Mongolia to New Zealand. Across England, cases have reached a historical peak, while rates across Europe in 2023 were triple the level compared to the rates from 2014.

“The approval of novel therapies for gonorrhoea is an significant and necessary advancement in the reality of growing infection rates, the spread of superbugs and the very limited treatment choices at this time.”

Medical experts are increasingly worried about the surge in drug-resistant strains. The World Health Organization has listed it as a "high-priority threat". Recent surveillance revealed that the effectiveness of key first-line drugs like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

Recent Drugs Gain Approval

Zoliflodacin, also known as Nuzolvence, was cleared by the US Food and Drug Administration in December for combating gonorrhoea. This STI can lead to major issues, including infertility. Experts hope that targeted use of this new drug will help slow the spread of drug resistance.

Gepotidacin, originating from the drugmaker GSK, was also approved in the same week. This treatment, which is employed against UTIs, was demonstrated in studies to be effective against drug-resistant strains of the gonorrhoea bacteria.

An Innovative Development Model

Zoliflodacin was the result of a innovative non-profit model for antibiotic development. The charitable organization GARDP partnered with the drug firm Innoviva to develop it.

“This approval represents a huge turning point in the management of multidrug-resistant gonorrhoea, which previously has been outpacing medical innovation.”

Testing Data and Worldwide Availability

According to data published in a prominent scientific publication, the new drug cured over nine in ten of genital gonorrhoea infections. This establishes an comparable level with the existing first-line therapy, which involves a dual-drug approach. The trial included over 900 volunteers from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its development partnership, the non-profit has the ability to register and commercialise the drug in many regions with limited resources.

Doctors treating patients have expressed hope. Access to a one-pill regimen such as this is hailed as a "critical tool" for public health efforts. This is viewed as crucial to lessen the impact of the disease for people and to halt the transmission of untreatable gonorrhoea worldwide.